Zevra therapeutics announces collaboration with rare-x and the sleep consortium as founding member of new sleep data initiative

New patent issued covering serdexmethylphenidate (sdx), the sole active pharmaceutical ingredient in kp1077, zevra's product candidate for the treatment of idiopathic hypersomnia (ih)
ZVRA Ratings Summary
ZVRA Quant Ranking